Literature DB >> 23318364

Kidney cancer in 2012: new frontiers in kidney cancer research.

Kriti Mittal1, Brian Rini.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23318364     DOI: 10.1038/nrurol.2012.256

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  6 in total

1.  Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Mark R Olsen; Gary R Hudes; John M Burke; William J Edenfield; George Wilding; Neeraj Agarwal; John A Thompson; David Cella; Akintunde Bello; Beata Korytowsky; Jinyu Yuan; Olga Valota; Bridget Martell; Subramanian Hariharan; Robert A Figlin
Journal:  J Clin Oncol       Date:  2012-03-19       Impact factor: 44.544

2.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Authors:  Brian I Rini; Bernard Escudier; Piotr Tomczak; Andrey Kaprin; Cezary Szczylik; Thomas E Hutson; M Dror Michaelson; Vera A Gorbunova; Martin E Gore; Igor G Rusakov; Sylvie Negrier; Yen-Chuan Ou; Daniel Castellano; Ho Yeong Lim; Hirotsugu Uemura; Jamal Tarazi; David Cella; Connie Chen; Brad Rosbrook; Sinil Kim; Robert J Motzer
Journal:  Lancet       Date:  2011-11-04       Impact factor: 79.321

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

4.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 5.  Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

Authors:  Brett E Houk; Carlo L Bello; Bill Poland; Lee S Rosen; George D Demetri; Robert J Motzer
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-05       Impact factor: 3.333

6.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

  6 in total
  3 in total

1.  Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma.

Authors:  Erik Hedrick; Syng-Ook Lee; Gyungeun Kim; Maen Abdelrahim; Un-Ho Jin; Stephen Safe; Ala Abudayyeh
Journal:  PLoS One       Date:  2015-06-02       Impact factor: 3.240

2.  Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.

Authors:  Roberto Pili; Glenn Liu; Sreenivasulu Chintala; Hendrick Verheul; Shabnam Rehman; Kristopher Attwood; Martin A Lodge; Richard Wahl; James I Martin; Kiersten Marie Miles; Silvia Paesante; Remi Adelaiye; Alejandro Godoy; Serina King; James Zwiebel; Michael A Carducci
Journal:  Br J Cancer       Date:  2017-02-21       Impact factor: 7.640

3.  Impact of the Discordance Between Scales of Memorial Sloan-Kettering Cancer Center and International Metastatic Renal Cell Carcinoma Database Consortium in Patients' Prognosis With Metastatic Renal Cancer.

Authors:  Hiram Josue Grimaldo-Roque; Erika Adriana Martinez-Castaneda; Mariana G Morales-Garcia; Jorge Luis Leal-Hidalgo; Valeria M Torres-Guillen; Rita Dorantes-Heredia; Daniel Motola-Kuba; Jose Manuel Ruiz-Morales
Journal:  World J Oncol       Date:  2022-04-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.